Clinical Trials for Diabetic Macular Edema

Diabetic macular edema (DME) is a complication of diabetes in which fluid leaks into the macula -- the central part of the retina responsible for sharp, detailed vision. It is the leading cause of vision loss in working-age adults with diabetes, and it is treatable. But treatment requires specialty anti-VEGF injections, and coverage barriers can delay care in ways that put vision at real risk.

Clinical trials are actively developing better treatments for DME -- including longer-lasting injections, gene therapy, and combination approaches that may reduce the burden of frequent office visits. According to the National Eye Institute, about 7.7 million Americans have diabetic retinopathy, of which DME is a significant complication.

What Types of Trials Are Available?

Extended-durability anti-VEGF trials are studying new formulations and delivery methods designed to last longer between injections. This is a significant quality-of-life issue for many people managing DME alongside the demands of diabetes care. Gene therapy trials are exploring whether a one-time gene therapy intervention could enable sustained VEGF suppression without ongoing injections -- a potential breakthrough for people who struggle with the frequency of current treatment. Steroid implant trials are studying intravitreal corticosteroid devices as adjuncts for people who have not adequately responded to anti-VEGF therapy alone. Systemic diabetes control and DME trials are studying whether optimized blood sugar management, combined with retinal treatment, improves visual outcomes beyond either approach alone.

Search ClinicalTrials.gov for currently recruiting trials.

Am I Eligible?

Common eligibility factors for DME trials include:

- Confirmed DME diagnosis (typically by OCT showing retinal thickening)

- Specific visual acuity range at enrollment

- Diabetes type and duration, and HbA1c level

- Prior anti-VEGF treatment history (some trials enroll treatment-naive participants; others require prior treatment)

- Stable systemic diabetes management

- No recent eye surgery in the study eye

Your retinal specialist can review your recent imaging and systemic diabetes status to assess trial fit. Talk to your doctor before making any decisions about your treatment.

What If My Insurance Denied My Medication?

Anti-VEGF injections for DME -- including aflibercept (Eylea), ranibizumab (Lucentis), bevacizumab (Avastin), and faricimab (Vabysmo) -- are frequently subject to prior authorization and step therapy requirements. Delays in treatment can allow fluid to accumulate and vision to worsen.

If your retinal specialist has prescribed an anti-VEGF injection and your insurer has denied it, appeal promptly and document medical urgency. At the same time, a clinical trial studying a similar or newer agent may offer access to treatment while your appeal proceeds.

Ellen can help you figure out your next step. Start with Ellen →

Frequently Asked Questions

Are clinical trials for diabetic macular edema free?

In most cases, yes. Trial sponsors (pharmaceutical companies, universities, or the NIH) cover the cost of the experimental treatment. You may still have costs for routine care — like doctor visits or standard tests — depending on your insurance. Always ask the trial coordinator what costs you might be responsible for before enrolling.

How do I find diabetic macular edema trials near me?

The best place to start is ClinicalTrials.gov, the official registry of all trials in the US. Search by condition name and filter by your location. Your specialist can also help identify trials at academic medical centers in your region.

Can I join a trial after being denied Eylea or Vabysmo?

Yes, and in many cases a denial can actually make you a stronger candidate — trials often enroll patients who have not responded to or cannot access standard treatments. Talk to your doctor about whether your denial history makes you eligible for open trials studying Eylea or Vabysmo or similar medications.